That cerebral infarct volume reduction, identified following exogenous Lin−/Sca1+ cell administration, was abrogated when Lin−/Sca1+ cell administration occurred concomitant to SDF1-A antibody administration provides further support to this hypothesis (Figure 4). This evidence concerns the gene CXCL12 and cerebral infarction.